Though GSK has put considerable effort into developing pharmacological treatments for gynecological cancers—including Zejula, ...

GSK acquired Zejula as part of its $5.1 billion takeover of Tesaro in 2018, along with other oncology drug candidates, including latecomer PD-1 inhibitor Jemperli (dostarlimab) and others ...

GSK's major growth drivers, Shingrix and Arexvy, along with recent legal progress, make its current undervaluation ...

Oncology sales rose 94%, driven by strong patient demand for Jemperli, Ojjaara and Zejula. Jemperli added £130 million to GSK ...

GSK further contends that Moderna got its hands on technical know-how tied to the company’s mRNA vaccine platform by “hiring several former Novartis and GSK employees with first-hand knowledge.” ...

GSK is delivering consistent financial performance ... so it's important Jemperli is now available to these patients. Zejula's growth continued in Q3 driven by U.S. pricing effects and high ...

Also Read: Just After Pfizer’s RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population Specialty Medicine sales increased ...

Full Year 2024 Guidance: 7% to 9% sales growth, 11% to 13% profit growth. GSK PLC (NYSE:GSK) reported a 9% sales growth and 19% profit growth year-to-date, reflecting strong performance in ...

GSK's Q3 earnings beat estimates but sales miss the same. The company also lowers its outlook for vaccine sales for the rest of the year due to weak U.S. demand.